Introduction
============

Attention-deficit/hyperactivity disorder (ADHD), the most common neuropsychiatric disorder in children, with a 5.2% worldwide pooled prevalence rate,^[1](#bib1){ref-type="other"}^ causes significant academic, behavioral and social impairment throughout the life span.^[2](#bib2){ref-type="other"},\ [3](#bib3){ref-type="other"}^ The phenotype consists of extreme manifestations of continuous traits, including hyperactivity, impulsivity, and dysfunction in executive and self-regulatory skills that involve working memory, temporal organization, planning, organizing, maintaining focus, effort and motivation.^[4](#bib4){ref-type="other"},\ [5](#bib5){ref-type="other"}^

Brain studies of patients with ADHD have shown abnormalities in frontal-striatal and cerebellar circuitry.^[6](#bib6){ref-type="other"},\ [7](#bib7){ref-type="other"}^ Although dopaminergic and noradrenergic medications are clinically effective,^[8](#bib8){ref-type="other"}^ animal models provide support for the involvement of additional molecular pathways.^[9](#bib9){ref-type="other"}^ Twin studies estimate a heritability of up to 90%,^[10](#bib10){ref-type="other"}^ indicating a substantial genetic contribution. However, genetic association studies thus far have not identified any genes definitively conferring major risk.^[10](#bib10){ref-type="other"},\ [11](#bib11){ref-type="other"}^ ADHD comorbidity occurs in many neuropsychiatric disorders, including autism, Tourette syndrome and in children with schizophrenic parents.^[12](#bib12){ref-type="other"},\ [13](#bib13){ref-type="other"}^

Recently, investigations of autism^[14](#bib14){ref-type="other"},\ [15](#bib15){ref-type="other"},\ [16](#bib16){ref-type="other"}^ and schizophrenia^[17](#bib17){ref-type="other"},\ [18](#bib18){ref-type="other"},\ [19](#bib19){ref-type="other"},\ [20](#bib20){ref-type="other"},\ [21](#bib21){ref-type="other"}^ have implicated *de novo* and/or rare copy number variations (CNVs) as being potentially pathogenic in these disorders. These findings are consistent with a genetic model where any of a large number of individually rare mutations of recent origin, and affecting a substantial number of genes involved in neurodevelopment, can contribute to disease predisposition. Given the highly heritable and variable nature of ADHD, we therefore hypothesized that individually rare and inherited structural variants might contribute to disease risk in ADHD, and that such variants are likely enriched within genes involved in neurological processes and neuropsychiatric disease. To our knowledge, this is the first report investigating the role of structural variants in ADHD.

Materials and methods
=====================

ADHD population
---------------

Attention-deficit/hyperactivity disorder families were recruited from pediatric and behavioral health clinics in the Philadelphia area. Inclusion criteria included families of European descent with an ADHD proband (age 6--18). Exclusionary criteria included prematurity (\<36 weeks), mental retardation, major medical and neurological disorders, pervasive developmental disorder, psychoses and major mood disorders. Blood collected from ADHD families was sent to the Rutgers University Cell and DNA Repository in New Jersey where lymphoblastoid cell lines were developed. Subsequently, DNA was extracted and returned to our laboratory for genotyping.

Healthy control population
--------------------------

Healthy control individuals were recruited from the Philadelphia region through the Hospital\'s Health Care Network, including four primary care clinics and several group practices and outpatient practices that performed well child visits. Eligibility criteria for this study included both of the following: disease-free children (age range: 6--18 years) and parents of these children who had high-quality, genome-wide genotyping data from blood samples with no serious underlying medical disorder, including, but not limited to neurodevelopmental disorders, cancer, chromosomal abnormalities and known metabolic or genetic disorders. DNA samples from a small set of parents of the participating children were also genotyped and used to assess CNV heritability patterns. A total of 2026 individuals passed all quality control measures and qualified for the study. All participants and/or their parents signed an informed consent permitting the use of their genotypes and health-care records for the study. Ancestry informative markers available on the HumanHap550 BeadChip^[22](#bib22){ref-type="other"}^ were used to evaluate these 2026 participants to confirm ethnicity.

Measures
--------

A child psychiatrist assessed diagnostic status of ADHD probands by administering the Schedule for Affective Disorders and Schizophrenia for School Age Children -IV Revised (K-SADS P-IVR).^[23](#bib23){ref-type="other"}^ Intraclass correlations between raters for the diagnostic symptoms of the major disorders were assessed through videotape reviews. Parental ADHD was assessed using the ADHD Self-Report Scale.^[24](#bib24){ref-type="other"},\ [25](#bib25){ref-type="other"}^ Parents provided consent and children assent.

Genotyping
----------

All samples were uniformly genotyped at the Center for Applied Genomics at the Children\'s Hospital of Philadelphia. DNA samples were surveyed for quality both by optical density spectrophotometry and the PicoGreen assay (Molecular Probes, Eugene, OR, USA).^[26](#bib26){ref-type="other"}^ Samples judged to be of sufficient quality for genotyping were assayed on the Illumina Infinium II HumanHap550 BeadChip (Illumina, San Diego, CA, USA) as previously described.^[27](#bib27){ref-type="other"}^ As BeadChip images were collected, intensity values were determined for all instances of each bead type, and data files were created that summarized intensity values for each bead type. A bead pool manifest was loaded into BeadStudio along with intensity data for the samples. BeadStudio uses a normalization algorithm to minimize BeadChip to BeadChip variability. Once the normalization was complete, a clustering algorithm was used to evaluate cluster positions for each locus and assign individual genotypes. logR ratios (LRRs) and B allele frequencies were calculated for every single nucleotide polymorphism (SNP) based on these clusters and the genotype of each SNP.

CNV detection and analysis
--------------------------

The Illumina BeadStudio 3.0 software package was used for initial CNV detection analysis. LRRs and B allele frequencies were first exported from BeadStudio. LRR values were used as an additional sample-wide genotype quality control measure, and LRRs with a standard deviation above 0.35 were excluded from the study. Chromosomes were segmented on the basis of LRRs, using the circular binary segmentation algorithm implemented in the R statistical package module DNAcopy 1.7 (<http://www.bioconductor.org/>). We used the reference clusters for each SNP that were supplied by Illumina from a set of HapMap samples. As these samples are a mixture of males and females, the Log R Ratio distribution for the X chromosome differs from that of the autosomal chromosomes. Accordingly, differing thresholds were chosen based on known samples with X chromosome deletions and duplications. For autosomal chromosomes, we used threshold of acceptance values of −2, −0.3 and 0.25 for the mean LRRs of potential homozygous deletions, hemizygous deletions and duplications, respectively. For males, X chromosome thresholds of −2 and 0.1 were used for hemizygous deletions and duplications, respectively. For females, X chromosome thresholds of −1.5, −0.1 and 0.6 were used for homozygous deletions, hemizygous deletions and duplications, respectively. Initial CNV calls were then further filtered by their B allele frequency distribution patterns. Autosomal and female chromosome X B allele frequency patterns for duplications and homozygous deletions were required to fit a three-copy mode more closely than a two-copy mode. In addition, paucity of AB alleles in the segment was a requirement for calling the segment a hemizygous deletion. For comparative purposes, two CNVs were considered the same or non-unique if their overlapping region contained at least 80% of the SNPs comprising each CNV. We limited the CNV set for consideration to those spanning ⩾10 consecutive SNPs after conducting a trial of \>200 experimentally validated CNVs that showed \>99% accuracy for our CNV prediction method using this threshold. In addition, all CNVs meeting quality and experimental design metrics were independently assessed by inspection of each BeadStudio visualization.

Literature analysis
-------------------

Literature analysis used the set of 175 non-olfactory receptor genes overlapping CNVs unique to ADHD probands relative to controls. Literature records associated with these genes were assessed by an expert reviewer to determine whether genes had been previously suggested as candidate genes in neuropsychiatric or neural functioning disorders. Accepted evidence was restricted to significant or suggestive findings in genetic association or structural variation studies performed either as gene-specific surveys or genome-wide. To confirm the literature review process, we determined whether biomedical literature mentioning the ADHD CNV gene set preferentially referred to other neuropsychiatric disorders. As the ADHD gene set was acquired using an independent genetic technique that had no memory of prior studies, a null hypothesis would predict that MEDLINE abstracts mentioning the 175 ADHD genes would not be enriched for terms related to autism or schizophrenia, the two disorders comorbid with ADHD with sufficient literature sampling sizes. For this process, sets of genes co-mentioned with terms related to autism or schizophrenia in MEDLINE abstracts and abstract metadata were identified, using the literature mining tool FABLE (<http://fable.chop.edu>), the Phenopedia tool of the gene resource HuGE Navigator (<http://hugenavigator.net/>), and for autism queries, the autism gene database AutDB (<http://www.mindspec.org/autdb.html>). FABLE query terms used were 'autism\' and/or 'schizophrenia\', with or without terms relating to structural variation (see [Table 1](#tbl1){ref-type="table"}). HuGE Navigator concepts used were *Autistic Disorder*, *Schizophrenia*, and for controls, *Meningioma*, *Astrocytoma*, *Parkinson Disease*, and *Alzheimer Disease*. For AutDB, we used all genes listed as candidates as the test group. For all three resources, the sets of genes implicated in the queried diseases were tested for significantly enriched representation of ADHD CNV genes using the single-sample proportions test.

*In silico* functional analysis
-------------------------------

Functional and pathway analyses were carried out using the Ingenuity Pathway Analysis software package (<http://www.ingenuity.com>). Gene Ontology (GO) analysis was carried out using the Explain software from Biobase, as part of the Biobase Knowledgebase (<http://bkl.biobase.de/cgi-bin/bkl/idb/1.0/login.cgi?previous_url=searchengine/start.cgi>). For both sets of analyses, RefSeq genes overlapping the rare and inherited ADHD CNVs were extracted and input into the requisite pathway analysis models.

Validation
----------

### Fluorescence *in situ* hybridization

Fluorescence *in situ* hybridization (FISH) validation of the *GRM5* deletion was performed on metaphase spreads prepared from the participant-derived lymphoblastoid cell lines using standard methodology. Chromosomes were visualized by counter staining with 4,6-diamidino-2-phenylindole. FISH was performed using fosmid W12-2219g4 and BAC RP11-697e14. FISH analysis was carried out as previously described.^[28](#bib28){ref-type="other"}^ Bacterial artificial chromosomes and fosmids were isolated using the UltraClean plasmid kit (MoBio Labs Inc., Carlsbad, CA, USA) and probes were labeled with Spectrum Red or Green (Abbott Molecular Inc., IL, USA) by nick translation. FISH images were captured using MacProbe software (Applied Imaging, San Jose, CA, USA).

### Real-time quantitative PCR

Primers and probes used to detect *PTPRD* CNVs were designed using Primer Express software (Applied Biosystems, Foster City CA, USA). Primers were purchased from Integrated DNA Technologies (Coralville, IA, USA). Primer sequences are as follows: F primer: 5′-ACATTTCAGAATATCCATCCTTTGG-3′ R primer: 5′-TGCTAATTCGTCCCAGAACGA-3′. Probes were purchased from Operon Biotechnologies, Inc. (Huntsville, AL, USA). The probe 5′-TGGCAGCCAAGCTAAAGCAAATCCTTG-3′ was labeled with FAM (6-carboxy-fluorescine) along with a quencher (BHQ 1; Biosearch Technologies, Novato, CA, USA). Dilutions of control gDNA of 40, 20, 10, 5 and 2.5 ng μl^--1^ were used as comparators to test DNA samples diluted to ∼10 ng μl^--1^. All DNAs, probes and primers were diluted in low EDTA TE buffer. Reactions were run on the ABI 7500 Fast Real-time PCR system (Applied Biosystems) using the following cycling parameters: one cycle at 95 °C for 20 s, followed by 40 cycles at 95 °C for 3 s and 60 °C for 30 s. Each reaction was carried out in a total volume of 20 μl containing 1 × Taqman Fast Universal PCR Master mix, 900 n[M]{.smallcaps} of each primer and 250 n[M]{.smallcaps} probe. A total of 2.5 μl of DNA was added to each reaction. Reactions were carried out in triplicate. Quantitative PCR analysis software supplied by the manufacturer (Applied Biosystems) was used to calculate standard curves and quantify samples. A control probe set within the albumin gene was used as a reference to determine copy number. A ratio of 1 for assay/albumin was viewed as normal copy number.

Results
=======

The ADHD cohort comprised of 335 complete parent--child trios of European descent recruited from pediatric and behavioral clinics that passed genotype and CNV analysis quality metrics (see Methods). A set of 2026 ethnically matched, disease-free children was used as a healthy control group. All samples were genotyped using the Illumina HumanHap550K BeadChip and a single consistent protocol. Genotype data were uniformly analyzed for CNVs using Illumina\'s BeadStudio software in combination with a customized adaptation of the circular binary segmentation algorithm.^[29](#bib29){ref-type="other"}^

Comparison of the CNV sets identified in the 335 probands and the healthy controls showed comparable overall frequencies. ADHD patients had a mean of 27.4 CNVs vs 26.9 for healthy controls (*P*=0.28). No significant differences were seen for deletions (*P*=0.67) or duplications (*P*=0.33). Moreover, no difference was seen in CNV size between the patient and control groups, either overall (*P*=0.91), or for duplications (*P*=0.43) or deletions (*P*=0.12).

We focused on rare inherited variants matching the following criteria: size spanning ⩾10 consecutive SNPs for deletions and ⩾20 SNPs for duplications, and present in at least one parent along with one or more related probands but not in the healthy control set. A total of 222 CNVs (158 deletions and 64 duplications) from 154 probands met these criteria ([Supplementary Table S1](#sup1){ref-type="other"}). The median variant size was 102 kb (range from 7.75 to 1775 kb) with 116 of the CNVs (52%) overlapping one or more genes. The CNVs encompassed or overlapped 229 distinct genes, 23 of which were associated with CNVs from multiple individuals. The largest family of genes affected was the olfactory receptor superfamily (54 genes, including 35 genes associated with a single duplication). Numerous recent studies have shown that olfactory receptors are rapidly evolving, mainly because of an unusually high rate of structural variation and close association of many family members with segmental duplications.^[30](#bib30){ref-type="other"},\ [31](#bib31){ref-type="other"},\ [32](#bib32){ref-type="other"}^ As these genes are overrepresented in our CNV set and present a skewed distribution that might bias our ability to detect pathway enrichment, these genes were removed from subsequent analyses. This reduced our ADHD CNV gene set to 175 genes.

To determine whether the ADHD gene set preferentially contained genes of neurological significance, we first looked for evidence in the literature for prior implication of these genes in neuropsychiatric disorders. An independent, systematic assessment of MEDLINE abstracts, HUGE Navigator, the autism gene database AutsDB and the candidate gene database SchizophreniaGene showed that genes implicated in autism and/or schizophrenia in any of these resources were significantly enriched in ADHD CNV genes ([Table 1](#tbl1){ref-type="table"}), but not for other brain-related disorders ([Supplementary Table S2](#sup1){ref-type="other"}). Manual review of literature associated with the 175 genes determined that at least 22 (28 total CNVs) of these genes were previously implicated by genetic studies in various neurological and neuropsychiatric disorders ([Tables 2](#tbl2){ref-type="table"} and [3](#tbl3){ref-type="table"}), including Tourette syndrome (two genes), autism (four genes) and schizophrenia (15 genes). Furthermore, eight of these 22 genes (11 total CNVs) have been very recently identified in structural variation studies carried out on autism and schizophrenia cohorts: *A2BP1*, *PARK2*, *NKAIN2*, *DPP6*, *CNTNAP2*, *IMMP2L*, *AUTS2* and *GRM7*.

We next determined if our ADHD gene set was enriched for particular biological and disease processes. Using Ingenuity Pathway Analysis, the process categories *neurological disease*, *psychological disorders*, *nervous system development and function* and *behavior* were among the most significantly enriched categories in the ADHD gene set, even after application of a multiple test correction (MTC) ([Table 4](#tbl4){ref-type="table"}). Four of the six most highly enriched GO Biological Process categories were *learning*, *cell adhesion, central nervous system development* and *hindbrain development* ([Supplementary Table S3](#sup1){ref-type="other"}), with *learning* and *cell adhesion* trending towards statistical significance after MTC application. When GO Biological Process analysis was restricted to genes that overlapped only CNV deletions, the classes representing *learning* and *hindbrain development* retained MTC-applied significance ([Table 5](#tbl5){ref-type="table"}). ADHD CNV genes associated with learning and cognition included *ATM*, *CTNND2*, *GRM5*, *GRM7*, *PARK2*, *PTPRD* and *UNC13C*. As an additional control to show the specificity and independence of the inclusion variables, the same CNV inclusion criteria and analysis strategies were reapplied using a large set of parent--child trios for congenital heart disease. The enriched pathway spectrum was almost entirely dissimilar in the cardiovascular cohort, and no neurological function classes were found significant, even without MTC application.

Several of the most highly enriched GO cellular component terms involved neural functioning, although no terms were sufficiently enriched to pass significance testing after MTC application. Three genes (*GRM5*, *GRM7* and *PARK2*) were associated with the GO term *postsynaptic membrane*, four genes (*GRM5*, *GRM7*, *PARK2* and *UNC13C*) with *synapse*, two genes (*CHN2* and *UNC13C*) with *synaptosome* and two genes *(CPLX2*, *GOSR1*) with the *SNARE complex*, members of which mediate synaptic vesicle fusion.

Two genes, *PTPRD* and *GRM5*, were especially intriguing as putative candidate genes for ADHD. Hemizygous deletions involving the protein tyrosine phosphatase gene, *PTPRD*, were detected in four unrelated ADHD probands, spanning exon 2, exons 3--9, exon 9 and intron 2 of the gene, respectively ([Supplementary Figure S1](#sup1){ref-type="other"}). *PTPRD* CNVs were experimentally validated by quantitative PCR in two probands ([Supplementary Table S4](#sup1){ref-type="other"}). The deletion was confirmed by q-PCR in both probands as well as in a transmitting parent for the one case where DNA was available (130-386-1). Two of the four ADHD probands with *PTPRD* deletions reported symptoms consistent with restless legs syndrome (RLS), which shares high rates of bidirectional comorbidity as well as dopaminergic dysfunction with ADHD.^[33](#bib33){ref-type="other"},\ [34](#bib34){ref-type="other"}^ Intriguingly, a recent genome-wide association study has implicated *PTPRD* as a locus for RLS.^[35](#bib35){ref-type="other"}^ Moreover, genetic variants of *PTPRD* associate with bronchial asthma,^[36](#bib36){ref-type="other"}^ which is reported to occur at higher rates in children with ADHD,^[37](#bib37){ref-type="other"}^ and RLS patients have been shown to have increased use of asthma medications.^[38](#bib38){ref-type="other"}^ Studies of the *PTPRD* gene in mice show high expression in the hippocampus, the only brain region reported to be enlarged in ADHD,^[39](#bib39){ref-type="other"}^ along with involvement in spatial learning, long-term potentiation and axonal guidance of motor neurons.^[40](#bib40){ref-type="other"},\ [41](#bib41){ref-type="other"},\ [42](#bib42){ref-type="other"}^

Catecholaminergic neurotransmission is widely studied in ADHD and has yielded several candidate genes conferring a small amount of risk, suggesting a potential role for additional neurotransmitter systems. We found a maternally derived *GRM5* CNV in three siblings. Both *GRM5* and *GRM7* (above) belong to the glutamatergic receptor gene family hypothesized to play a role in ADHD.^[43](#bib43){ref-type="other"},\ [44](#bib44){ref-type="other"},\ [45](#bib45){ref-type="other"}^ The *GRM5* variant, a hemizygous deletion of 82 kb (11 SNPs; [Supplementary Figure S2](#sup1){ref-type="other"}), showed uniparental inheritance and was experimentally validated by FISH ([Figure 1](#fig1){ref-type="fig"}). Neuropsychiatric assessment indicated that all three children in this family, one 18-year-old male and two females with ages 15 and 11, met the criteria for ADHD with significant impairment since early childhood. All three children showed some improvement in symptoms with medications but persistent overall dysfunction in academic, social and behavioral spheres in spite of superior IQ levels. Assessment of the mother using the ADHD Self-Report Scale indicated a likelihood of ADHD (scores of 20 for part A and 12 for part B).^[46](#bib46){ref-type="other"}^ The mother, and to a lesser extent, all three children, display problems with spatial orientation, a characteristic also observed in the *GRM5* null mouse.^[47](#bib47){ref-type="other"}^ Intriguingly, *GRM5* null mice also have deficiencies in long-term potentiation^[47](#bib47){ref-type="other"}^ as well as an increase in anxiety-like behavior that can be reduced with *GRM5* antagonists.^[48](#bib48){ref-type="other"}^ ADHD frequently occurs in Fragile X syndrome,^[49](#bib49){ref-type="other"}^ and *GRM5* antagonists have recently been shown to de-repress startle inhibition in Fragile X (*FMR1*) null mice.

In addition to the parent with the *GRM5* variant, we were able to obtain ADHD Self-Report Scales for an additional 20 parents with CNVs overlapping any of the 22 top candidate genes from [Table 2](#tbl2){ref-type="table"} (presented in [Supplementary Table S5](#sup1){ref-type="other"}). Two parents (for genes *IMMP2L* and *A2BP1*) met definitive criteria for adulthood ADHD (score of 24 and above on either section A or section B of the ASRS) and three parents (for genes *A2BP1, DPP6* and *PTPRD*) were likely to meet criteria (ASRS score 17--23 on either section). However, interpretation of this data is complex owing to our limited knowledge of adult ADHD and its relationship to the childhood form.

Discussion
==========

The CNV-associated gene set identified in our ADHD cohort did not have an excess of deletions or insertions compared with the controls. It was however significantly enriched for genes reported as candidates in other neuropsychiatric disorders and neurodevelopmental pathways.

In addition to *PTPRD* and *GRM5*, several genes in our ADHD CNV gene set are notable, particularly those eight previously reported to have CNVs in another neuropsychiatric disorder ([Tables 2](#tbl2){ref-type="table"} and [3](#tbl3){ref-type="table"}). The *A2BP1* gene, whose protein product binds to the ataxin-2 gene responsible for spinocerebellar ataxia-2, was found overlapping with three rare inherited copy number changes in our ADHD probands, and it was also seen in rare *de novo* copy number changes involving only this gene in a schizophrenic and an autistic proband. Translocations and CNVs disrupting *A2BP1* have been reported in patients with autism, schizophrenia, epilepsy and mental retardation. The *PARK2*, *NKAIN2* and *DPP6* genes were found overlapping with separate rare inherited copy number changes in our study as well as in CNVs overlapping only the same respective genes in a schizophrenia study. Genomic deletions of the neurexin superfamily gene, *CNTNAP2*, were also identified in three individuals with schizophrenia and epilepsy. Allelic variants of the *CNTNAP2* gene have been found to be associated with autism in three recent studies. Chromosomal rearrangements of both the *CNTNAP2* and *IMMP2L* genes have been reported in patients with Tourette syndrome, and the *IMMP2L* gene is present within the 7q22 *AUTS1* locus identified by several autism association studies. Similarly, chromosomal rearrangements disrupting the *AUTS2* gene have been reported in five autism patients. Finally, a rare copy number variant in a schizophrenic patient was found to overlap with the glutamatergic receptor *GRM7*. We observed an ADHD proband with a CNV in *GRM7* who also presented with anxiety. The extinction of conditioned fear, blocked with downregulation of *GRM7*, suggests that some of these CNVs may potentially explain certain comorbidities frequently associated with ADHD.^[50](#bib50){ref-type="other"},\ [51](#bib51){ref-type="other"}^

Recent investigations of structural variation in autism and schizophrenia have found increased *de novo* and/or overall variation in diseased individuals, leading to the speculation that these diseases may have a sizable number of possible molecular etiologies.^[15](#bib15){ref-type="other"},\ [19](#bib19){ref-type="other"},\ [21](#bib21){ref-type="other"},\ [52](#bib52){ref-type="other"},\ [53](#bib53){ref-type="other"}^ To date, this theory is consistent with the general lack of success of genetic association studies in identifying common causative variants in neuropsychiatric disorders, including ADHD.^[54](#bib54){ref-type="other"}^ Our results further support this hypothesis, as we found a wide distribution of genes specifically affected by CNVs in our ADHD probands relative to controls, many of which were associated with neurodevelopmental pathways and disorders.

Although our CNV detection platform is of high resolution, common CNV regions are underrepresented; it remains to be determined whether use of a higher resolution platform or a sequencing approach would alter the distribution curve of implicated genes. Nevertheless, our approach has identified a number of intriguing candidates that support a potential role of CNVs in ADHD, and it also suggests a number of candidate genes that may help to explain the spectrum of phenotypic heterogeneity observed in ADHD and other neuropsychiatric disorders.
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![FISH validation of the *GRM5* CNV. Metaphase spreads from (**a**) the non-affected father and (**b**) an ADHD patient with the deletion hybridized with probes labeled with Spectrum red (red signal) or Spectrum green (green signal). FISH was performed using fosmid W12-2219g4 (red signal) specific for the *GRM5* deletion and BAC RP11-697e14, a control probe for the subtelomeric region of chromosome 11q (green signal). A portion of the *GRM5* gene, including the 82kb region deleted in this family, is part of a 325kb segmental duplication present in two copies on chromosome 11, one in 11q and the other in 11p. This results in the observation of two red signals for the *GRM5* probe in the non-deleted father (**a**), on both homologs of chromosome 11 indicated by white arrowheads. The annotated *GRM5* gene in the reference genome is present on 11q. In the deleted patient (**b**), the red signal on 11q is missing on one of the two chromosome 11 homologs, because of the deletion within the *GRM5* gene, (indicated by a blue arrowhead).](mp200957f1){#fig1}

###### 

Enrichment of ADHD CNV genes in autism and schizophrenia candidate genes

  *Resource*          *Query*                              *Genes matching query*   *ADHD genes in query*   *Z-score*   *P-value*
  ------------------- ------------------------------------ ------------------------ ----------------------- ----------- -----------
  FABLE               Autism                               1003                     10                      1.14        0.127
  FABLE               Schizophrenia                        2516                     29                      13.19       \<*0.001*
  FABLE               Autism OR schizophrenia              2857                     32                      11.66       \<*0.001*
  FABLE               Autism AND CNV^a^                    438                      6                       13.35       \<*0.001*
  FABLE               Schizophrenia AND CNV^a^             998                      11                      5.73        \<*0.001*
  FABLE               Autism OR schizophrenia AND CNV^a^   1259                     16                      14.81       \<*0.001*
  HuGE navigator      Autistic disorder                    111                      1                       INS^b^      INS^b^
  HuGE navigator      Schizophrenia                        505                      9                       24.82       \<*0.001*
  HuGE navigator      Autistic disorder OR schizophrenia   561                      9                       20.46       \<*0.001*
  AutDB               All genes                            137                      5                       42.25       \<*0.001*
  SchizophreniaGene   All genes                            762                      10                      12.93       \<0.001

Abbreviations: ADHD, attention-deficit/hyperactivity disorder; CNV, copy number variation.

Query terms representing the concept of CNV: (genetics OR genomics) AND ('structural variation\' OR 'copy number\' OR association OR deletion OR duplication OR translocation).

INS, insufficient sample size to determine significance.

###### 

Genes in ADHD CNVs previously associated with neuropsychiatric and neurological disorders

  *Gene*       *Disorder(s)*^a^                                                 *Genomic reference(s)*^b^
  ------------ ---------------------------------------------------------------- ---------------------------
  *A2BP1*      [Schizophrenia]{.ul}; [autism]{.ul}; [mental retardation]{.ul}   (15, 21, 55, 56)
  *APOL4*      Schizophrenia                                                    \(57\)
  *ATM*        Ataxia-telangiectasia; neurodegeneration                         (58, 59)
  *AUTS2*      [Mental retardation and autism]{.ul}                             (60--62)
  *BLMH*       Alzheimer\'s disease                                             \(63\)
  *CHL1*       Schizophrenia                                                    \(64\)
  *CHN2*       Schizophrenia                                                    \(65\)
  *CNTNAP2*    [Schizophrenia]{.ul}; autism; Tourette syndrome                  (17, 58, 66--68)
  *CPLX2*      Schizophrenia                                                    \(69\)
  *CTNND2*     Mental retardation in cri du chat syndrome                       \(70\)
  *DPP6*       [Schizophrenia]{.ul}                                             \(21\)
  *GRM5*       Schizophrenia; Fragile X syndrome                                (71, 72)
  *GRM7*       [Schizophrenia]{.ul}                                             \(19\)
  *IMMP2L*     Autism; [Tourette syndrome]{.ul}                                 (73--76)
  *NKAIN2*     [Schizophrenia]{.ul}                                             \(21\)
  *PARK2*      [Schizophrenia]{.ul}                                             \(21\)
  *PDCD10*     Cerebral cavernous malformations                                 \(77\)
  *PTPRD*      Restless legs syndrome                                           \(33\)
  *RTN4*       Schizophrenia                                                    \(78\)
  *SEPP1*      Schizophrenia                                                    \(79\)
  *SERPINI1*   Schizophrenia                                                    (80, 81)
  *TACR3*      Schizophrenia                                                    \(82\)

Abbreviations: ADHD, attention-deficit/hyperactivity disorder; CNVs, copy number variations.

Underlined disorders indicate implication through CNV analysis.

References in [Table 2](#tbl2){ref-type="table"} are listed in the [Supplementary Materials](#sup1){ref-type="other"}.

###### 

ADHD CNVs within or overlapping genes previously implicated in neuropsychiatric and neurological disorders

  *Subject*   *Chromosome*   *Sequence start*   *Sequence end*   *Type*^a^   *\# of base pairs*   *\# of single nucleotide polymorphisms*   *Gene(s)*^b^
  ----------- -------------- ------------------ ---------------- ----------- -------------------- ----------------------------------------- --------------------------------------------
  130_080_3   2              55088956           55239201         dup         150246               40                                        *RTN4*
  130_351_3   3              38411              1118424          dup         1080014              268                                       *CHL1; CNTN6*
  130_068_3   3              7183953            7197236          het         13284                10                                        *GRM7* (intronic) *ZBBX; SERPINI2; WDR49;*
  130_237_3   3              168483422          169118601        dup         635180               91                                        *PDCD10; SERPINI1*
  130_083_3   4              104848417          104972885        dup         124469               25                                        *TACR3*
  130_231_3   5              11540585           11571704         het         31120                13                                        *CTNND2* (intronic)
  130_340_3   5              42613316           42859556         dup         246241               22                                        *GHR; SEPP1*
  130_100_3   5              175136520          175195299        het         58780                30                                        *CPLX2*
  130_347_3   6              124379082          124526687        het         147606               41                                        *NKAIN2* (intronic)
  130_213_3   6              162672945          162782313        het         109369               41                                        *PARK2* (intronic)
  130_220_3   6              162699792          162801747        dup         101956               38                                        *PARK2* (intronic)
  130_401_3   7              28982601           29309947         dup         327347               155                                       *CHN2*
  130_386_3   7              69624365           69726112         dup         101748               37                                        *AUTS2*
  130_197_3   7              110672863          110923287        het         250425               33                                        *IMMP2L*
  130_285_3   7              146179259          146237754        het         58496                12                                        *CNTNAP2* (intronic)
  130_249_3   7              153332837          153468471        het         135635               48                                        *DPP6*
  130_142_3   9              9084805            9178865          het         94061                42                                        *PTPRD*
  130_386_3   9              9168137            10067180         het         899044               317                                       *PTPRD*
  130_087_3   9              9985938            10020458         het         34521                10                                        *PTPRD* (intronic)
  130_093_3   9              10160101           10423023         het         262923               100                                       *PTPRD*
  130_230_3   11             88269449           88351661         het         82213                11                                        *GRM5* (intronic) *ACAT1; NPAT; ATM;*
  130_243_3   11             107520009          107885084        dup         365076               30                                        *C11orf65; KDELC2; EXPH5*
  130_358_3   16             6072599            6783832          dup         711234               398                                       *A2BP1*
  130_089_3   16             6753260            6841514          het         88255                44                                        *A2BP1* (intronic)
  130_214_3   16             7223181            7270339          het         47159                23                                        *A2BP1* (intronic)
  130_316_3   17             25613604           26191779         dup         578176               46                                        *BLMH* (six additional genes)
  130_055_3   22             34870070           34916870         het         46801                23                                        *APOL3; APOL4*

Abbreviations: ADHD, attention-deficit/hyperactivity disorder; CNVs, copy number variations.

Type of CNV: het, hemizygous deletion; hom, homozygous deletion; dup, duplication.

Gene(s) partially or fully contained within the corresponding CNV. The listed CNV is predicted to overlap one or more exons unless indicated by (intronic), where the CNV is predicted to lie entirely within a single intron of the named gene.

###### 

Gene functional categories significantly enriched in ADHD CNVs using ingenuity pathway analysis

  *Category*                                              *Genes in CNVs*                                                                                                           *Significance*^a^   *Adjusted significance*^b^
  ------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------- ------------------- ----------------------------
  *Diseases and disorders*                                                                                                                                                                              
   Infectious disease                                     *ATG5, ATM, F7, F10, MC2R, PARK2*                                                                                         7.56 × 10^−3^       2.32 × 10^−2^
   Genetic disorders                                      *ATM, EDARADD, F7, F10, GHR, HNF1B, MC2R, PARK2, SERPINI1, TNFRSF11A, ZCCHC2*                                             1.79 × 10^−4^       2.95 × 10^−2^
   Psychological disorders                                *APOL4, AUTS2, CHL1, CHN2, CNTNAP2, CPLX2, GRM5, RTN4, SEPP1, SERPINI1, TACR3*                                            5.28 × 10^−4^       3.08 × 10^−2^
   Neurological disease                                   *ACAT1, APOL4, ATM, AUTS2, CHL1, CHN2, CNTNAP2, CPLX2, F7, GRM5, MC2R, PARK2, RTN4, SEPP1, SERPINI1, TACR3*               5.28 × 10^−4^       4.58 × 10^−2^
   Hematological disease                                  *ATM, CUBN, F7, F10, MC2R*                                                                                                1.79 × 10^−4^       4.58 × 10^−2^
   Embryonic development                                  *FTO, HNF1B, IRX3, LHX1, MBTPS1, TCF21*                                                                                   8.82 × 10^−4^       4.98 × 10^−2^
                                                                                                                                                                                                         
  *Physiological system development and function*                                                                                                                                                       
   Hematological system development and function          *F7, F10, PRDM1*                                                                                                          8.82 × 10^−4^       1.55 × 10^−2^
   Behavior                                               *ATM, CHL1, CTNNA2, CTNND2, GRM5, GRM7, KLHL1, PARK2, PTPRD, SEPP1, UNC13C*                                               1.90 × 10^−5^       2.32 × 10^−2^
   Renal and urological system development and function   *CTNND2, F7, GHR, RTN4, SDK1, TCF21*                                                                                      6.32 × 10^−4^       3.83 × 10^−2^
   Nervous system development and function                *ATM, CDH4, CHL1, CHN2, CNTN6, CTNNA2, FTO, GHR, GRM5, GRM7, IRX3, PARK2, PTPRD, RTN4, SEMA3E, SEPP1, SERPINI1, UNC13C*   3.56 × 10^−4^       4.58 × 10^−2^

Abbreviations: ADHD, attention-deficit/hyperactivity disorder; CNVs, copy number variations.

Single test *P*-values.

Multiple test-corrected *P*-values using the Benjamini--Hochberg correction; only categories reaching a corrected statistical significance of *P*\<0.05 are shown.

###### 

Gene functional categories significantly enriched in ADHD CNV deletions using Gene Ontology (GO) analysis

  *GO term*                       *Genes in CNVs*                                                                          *Significance*^a^   *Adjusted significance*^b^
  ------------------------------- ---------------------------------------------------------------------------------------- ------------------- ----------------------------
  Learning                        *CTNND2, GRM5, GRM7, PARK2*                                                              9.20 × 10^−5^       9.48 × 10^−3^
  Response to organic substance   *ACACA, COLEC12, DUOX1, DUOX2, HNF1B*                                                    4.91 × 10^−4^       1.76 × 10^−2^
  Lipoprotein metabolic process   *APOL3, APOL4, COLEC12, PIGW*                                                            7.16 × 10^−4^       1.76 × 10^−2^
  Learning and/or memory          *CTNND2, GRM5, GRM7, PARK2*                                                              8.24 × 10^−4^       1.76 × 10^−2^
  Hindbrain development           *HNF1B, KLHL1, LHX1*                                                                     8.56 × 10^−4^       1.76 × 10^−2^
  Cell adhesion                   *AATF, CDH12, CDH4, CNTN6, CNTNAP2, CSMD1, CTNNA2, CTNNA3, CTNND2, GMDS, PCDH21, SDK1*   1.31 × 10^−3^       2.25 × 10^−2^

Abbreviations: ADHD, attention-deficit/hyperactivity disorder; CNVs, copy number variations.

Single test *P*-values.

Multiple test-corrected *P*-values using the Benjamini--Hochberg correction; only categories reaching a corrected statistical significance of *P*\<0.05 are shown.

[^1]: These authors contributed equally to this work.
